Results 151 to 160 of about 34,398 (227)

Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery

MedComm – Oncology, Volume 5, Issue 1, March 2026.
This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem, Atif Ali, Wajid Ali, Yuying Cheng, Zhibin Yan, Chaoyi Xia, Chenguang Liu, Caiyun Fu, Yiren Hu, Xi Wang   +9 more
wiley   +1 more source

CDK1-cyclin-B1-induced kindlin degradation drives focal adhesion disassembly at mitotic entry. [PDF]

Nat Cell Biol, 2022
Chen NP, Aretz J, Fässler R.
europepmc   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang, Xue Sun, Xinhao Han, Xingda Zhang, Wenzheng Wang, Hongbin Wang, He Ren, Lina Gu   +7 more
wiley   +1 more source

Spatial control of the APC/C ensures the rapid degradation of Cyclin B1

, 2023
Cirillo L, Young R, Veerapathiran S, Roberti A, Martin M, Abubacar A, Perosa C, Coates C, Muhammad R, Roumeliotis TI, Choudhary JS, Alfieri C, Pines J.   +12 more
europepmc   +1 more source

Structural basis of human separase regulation by securin and CDK1-cyclin B1. [PDF]

Nature, 2021
Yu J, Raia P, Ghent CM, Raisch T, Sadian Y, Cavadini S, Sabale PM, Barford D, Raunser S, Morgan DO, Boland A.   +10 more
europepmc   +1 more source

Molecular Glue Degraders Redefining Targeted Therapies From Discovery to Therapeutic Applications

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Molecular glue degraders (MGDs) constitute an emerging class of therapeutic agents poised to revolutionize the paradigm of targeted drug discovery. By reprogramming E3 ubiquitin ligases to degrade proteins of interest (POI) via a transient formation of a ternary complex mediated by protein–protein interactions, MGDs surpass the intrinsic limitations of
Jinfeng Wen, Jingtian Yu, Wuqiang Wen, Baishan Jiang   +3 more
wiley   +1 more source

Integrated analysis reveals survival-related genes promoting cholangiocarcinoma progression via G2/M cell cycle, with validation of cyclin B1 in tumor proliferation. [PDF]

Sci Rep
Jiang Q, Liu X, Yu W, Li Y, Du J, Jiang X, Li H.   +6 more
europepmc   +1 more source

Nivalenol affects Cyclin B1 level and activates SAC for cell cycle progression in mouse oocyte meiosis. [PDF]

Cell Prolif, 2022
Lu PS, Wang Y, Jiao L, Sun SC.
europepmc   +1 more source

Multifacet Roles of Cellular Senescence in Cancer: Mechanisms and Therapeutic Implications

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Cellular senescence shapes tumor progression through both antitumor and protumor mechanisms. Senescence triggered by telomere shortening restricts malignant transformation and limits tumor cell proliferation, while the senescence‐associated secretory phenotype (SASP) secretion enhances antitumor immunity by activating cytotoxic T cells.
Huajie Mao, Wanning Liu, Yuanyuan Su, Yuxuan Ma, Xiaodi Zhao, Yuanyuan Lu   +5 more
wiley   +1 more source

STOX1 Isoform A Promotes Proliferation and Progression of Hepatocellular Carcinoma by Dual Mechanisms of Transcriptionally Upregulation of Cyclin B1 and Activation of ROS-Dependent PTEN/AKT1 Signaling. [PDF]

Cancer Med
Jiang C, Wang C, Ao J, Liu Y, Sun F, Shi W, Guo Z, Wu Y, Gan L, Wu M, Zhi Y, Meng Z, Wu W, Wu J, Ye Y, Zhang X, Ren D, Pan M.   +17 more
europepmc   +1 more source